Cargando…
uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies
Urokinase plasminogen activator (uPA) is an extracellular matrix-degrading protease involved in cancer invasion and metastasis, interacting with plasminogen activator inhibitor-1 (PAI-1), which was originally identified as a blood-derived endogenous fast-acting inhibitor of uPA. At concentrations fo...
Autores principales: | Duffy, Michael J, McGowan, Patricia M, Harbeck, Nadia, Thomssen, Christoph, Schmitt, Manfred |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423643/ https://www.ncbi.nlm.nih.gov/pubmed/25677449 http://dx.doi.org/10.1186/s13058-014-0428-4 |
Ejemplares similares
-
Impact of uPA/PAI-1 and disseminated cytokeratin-positive cells in breast cancer
por: Märkl, Bruno, et al.
Publicado: (2019) -
Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer.
por: Schmitt, M., et al.
Publicado: (1997) -
Expression of uPA, tPA, and PAI-1 in Calcified Aortic Valves
por: Kochtebane, Najlah, et al.
Publicado: (2014) -
Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc
por: Kuhn, W, et al.
Publicado: (1999) -
Independent validation of stromal uPA in ABCSG-08: Level 1b evidence for the prognostic value of uPA immunohistochemistry
por: Singer, C.F., et al.
Publicado: (2022)